6j15 - Revision history

OCA at 09:57, 22 November 2023

2023-11-22T09:57:15Z

←Older revision		Revision as of 09:57, 22 November 2023
Line 3:		Line 3:
	<StructureSection load='6j15' size='340' side='right'caption='[[6j15]], [[Resolution\|resolution]] 2.60Å' scene=''>		<StructureSection load='6j15' size='340' side='right'caption='[[6j15]], [[Resolution\|resolution]] 2.60Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[6j15]] is a 6 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/ ] and [~~http~~://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6J15 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6J15 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[6j15]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6J15 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6J15 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.6Å</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=6j15 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6j15 OCA], [~~http~~://pdbe.org/6j15 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=6j15 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/6j15 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=6j15 ProSAT]</span></td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6j15 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6j15 OCA], [https://pdbe.org/6j15 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6j15 RCSB], [https://www.ebi.ac.uk/pdbsum/6j15 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6j15 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/PDCD1_HUMAN PDCD1_HUMAN]] Systemic lupus erythematosus;Multiple sclerosis. Systemic lupus erythematosus 2 (SLEB2) [MIM:[~~http~~://omim.org/entry/605218 605218]]: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.<ref>PMID:12402038</ref>	+	[https://www.uniprot.org/uniprot/PDCD1_HUMAN PDCD1_HUMAN] Systemic lupus erythematosus;Multiple sclerosis. Systemic lupus erythematosus 2 (SLEB2) [MIM:[https://omim.org/entry/605218 605218]: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.<ref>PMID:12402038</ref>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/PDCD1_HUMAN PDCD1_HUMAN]] Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. Possible cell death inducer, in association with other factors.<ref>PMID:21276005</ref>	+	[https://www.uniprot.org/uniprot/PDCD1_HUMAN PDCD1_HUMAN] Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. Possible cell death inducer, in association with other factors.<ref>PMID:21276005</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 20:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 6j15" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 6j15" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
		+	*[[Cell death protein 3D structures\|Cell death protein 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	[[Category: Mus musculus]]		[[Category: Mus musculus]]
-	[[Category: Chai, Y]]	+	[[Category: Chai Y]]
-	[[Category: Chen, D]]	+	[[Category: Chen D]]
-	[[Category: Gao~~, G F~~]]	+	[[Category: Gao GF]]
-	[[Category: Qi, J]]	+	[[Category: Qi J]]
-	[[Category: Tan, S]]	+	[[Category: Tan S]]
-	[[Category: Wang, H]]	+	[[Category: Wang H]]
-	[[Category: Yan, J]]	+	[[Category: Yan J]]
-	[[Category: Zhang, H]]	+	[[Category: Zhang H]]
-	~~[[Category: Complex structure]]~~	+
-	~~[[Category: Fg loop]]~~	+
-	~~[[Category: Immune system]]~~	+
-	~~[[Category: Tumor immunotherapy~~]]	+

OCA at 06:38, 6 November 2019

2019-11-06T06:38:04Z

←Older revision		Revision as of 06:38, 6 November 2019
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6j15 is ~~ON HOLD~~ ~~until Paper~~ Publication	+	==Complex structure of GY-5 Fab and PD-1==
		+	<StructureSection load='6j15' size='340' side='right'caption='[[6j15]], [[Resolution\|resolution]] 2.60Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[6j15]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/ ] and [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6J15 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6J15 FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6j15 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6j15 OCA], [http://pdbe.org/6j15 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6j15 RCSB], [http://www.ebi.ac.uk/pdbsum/6j15 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6j15 ProSAT]</span></td></tr>
		+	</table>
		+	== Disease ==
		+	[[http://www.uniprot.org/uniprot/PDCD1_HUMAN PDCD1_HUMAN]] Systemic lupus erythematosus;Multiple sclerosis. Systemic lupus erythematosus 2 (SLEB2) [MIM:[http://omim.org/entry/605218 605218]]: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.<ref>PMID:12402038</ref>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/PDCD1_HUMAN PDCD1_HUMAN]] Inhibitory cell surface receptor involved in the regulation of T-cell function during immunity and tolerance. Upon ligand binding, inhibits T-cell effector functions in an antigen-specific manner. Possible cell death inducer, in association with other factors.<ref>PMID:21276005</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Programmed cell death 1 (PD-1)/PD-1 ligand-1 (PD-L1)-blocking monoclonal antibodies (mAbs) have taken center stage for tumor immune checkpoint therapy. Identification of the "hotspots" on PD-1 for mAbs will help to develop next-generation oral deliverable agents with long-lasting efficacy. Here, we identified two PD-1-targeting mAbs, GY-5 and GY-14, with PD-1/PD-L1-blocking efficacy. Complex structural information revealed that both mAbs mainly bind to the FG loop of PD-1, which also contributes multiple interactions with PD-L1. The FG loop adopts substantially varied conformations upon binding to different mAbs, providing a novel targetable region for the development of PD-1-specific biologics and small chemical molecules. Glycosylation modifications of PD-1 could be observed in three of the four potential N-linked glycosylation sites. However, the binding of GY-5 and GY-14 to PD-1 was not affected by glycosylation. These findings broaden our understanding of the mechanism of anti-PD-1 mAbs and provide insight into the development of agents targeting PD-1.

-	~~Authors~~:	+	The FG Loop of PD-1 Serves as a "Hotspot" for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy.,Chen D, Tan S, Zhang H, Wang H, He W, Shi R, Tong Z, Zhu J, Cheng H, Gao S, Chai Y, Qi J, Xiao M, Yan J, Gao GF iScience. 2019 Apr 26;14:113-124. doi: 10.1016/j.isci.2019.03.017. Epub 2019 Mar , 21. PMID:30952089<ref>PMID:30952089</ref>

-	~~Description~~:	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased~~ Structures]]	+	</div>
		+	<div class="pdbe-citations 6j15" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Large Structures]]
		+	[[Category: Mus musculus]]
		+	[[Category: Chai, Y]]
		+	[[Category: Chen, D]]
		+	[[Category: Gao, G F]]
		+	[[Category: Qi, J]]
		+	[[Category: Tan, S]]
		+	[[Category: Wang, H]]
		+	[[Category: Yan, J]]
		+	[[Category: Zhang, H]]
		+	[[Category: Complex structure]]
		+	[[Category: Fg loop]]
		+	[[Category: Immune system]]
		+	[[Category: Tumor immunotherapy]]

OCA at 05:22, 6 March 2019

2019-03-06T05:22:34Z

←Older revision		Revision as of 05:22, 6 March 2019
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6j15 is ON HOLD	+	The entry 6j15 is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "6j15" [edit=sysop:move=sysop]

2019-01-02T04:52:01Z

Protected "6j15" [edit=sysop:move=sysop]

←Older revision

Revision as of 04:52, 2 January 2019

OCA: New page: '''Unreleased structure''' The entry 6j15 is ON HOLD Authors: Description: Category: Unreleased Structures

2019-01-02T04:52:00Z

New page: '''Unreleased structure''' The entry 6j15 is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 6j15 is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]